Mobile Streams posted a 173 per cent increase in revenues for the last half of 2012.

The provider of mobile content - including apps, games and eBooks - generated revenues of £23m, compared to £8.4m for the same period a year ago.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) were also significantly ahead of the same period in the prior year, the group said.

The company was debt free with cash of £2.2m at December 31st, up from £0.7m the previous year.

"Mobile Streams continued to grow strongly in the first six months of the new financial year," Chief Executive Officer, Simon Buckingham, said.

"The ongoing improvement in the company's revenues, profits and cash generation was driven primarily by solid growth in the company's mobile internet subscriber base in the Latin America region, primarily in Argentina, Mexico and Colombia."

He said the active mobile internet subscriber base surpassed 2.7m, compared to 1.25m in 2011.

The company will continue to add new markets including Brazil to its mobile internet rollout this year, he added.



Scancell has published its unaudited interim results for the six month period to October 31st, showing an overall operating loss of 989,981 pounds.

This compared to a loss of £941,674 in the corresponding period in 2011.

The cash at bank on October 31st was £2.6m compared to £3.3m on April 30th.

In spite of the slight increase in operating loss, the group reported encouraging preliminary results from the Part 1 of the Phase 1/2clinical trial for its SCIB1 melanoma vaccine and the receipt of an approval to dose an extra group of patients with a higher, 8.0mg, dose of the vaccine.

David Evans, Chairman of Scancell, commented: "During 2013, the assessment of a higher dose in patients with evaluable disease and the future assessment of immune response in part two of the clinical trials should provide further evidence to support the use of ImmunoBody vaccines for the treatment of cancers."

He added: "Whilst at an early stage with the new Moditope technology platform, the board is aware that the opportunities could be considerable and, with its existing ImmunoBody technology is confident that the company is well placed to create increasing value for shareholders."

Related share prices